Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials

BACKGROUND: Previous studies in patients with rheumatoid arthritis (RA) have shown that switching to tocilizumab (TCZ) monotherapy (TCZ(MONO)) or combination therapy (TCZ(COMBI)) with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is efficacious in reducing disease activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Teitsma, Xavier M., Marijnissen, Anne Karien A., Bijlsma, Johannes W. J., Lafeber, Floris P. J., Jacobs, Johannes W. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034420/
https://www.ncbi.nlm.nih.gov/pubmed/27658491
http://dx.doi.org/10.1186/s13075-016-1108-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034420/
https://www.ncbi.nlm.nih.gov/pubmed/27658491
http://dx.doi.org/10.1186/s13075-016-1108-9

Ejemplares similares